Why InflaRx N.V.’s (IFRX) Stock Is Down 6.20%
As of Thursday, August 27, InflaRx N.V.’s IFRX share price has dipped by 6.20%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Commentary & Analysis
Why InflaRx N.V.’s (IFRX) Stock Is Up 7.27%
As of Friday, August 07, InflaRx N.V.’s IFRX share price has surged by 7.27%, which has investors questioning if this is right time to sell.Michael Rose
Why InflaRx N.V.’s (IFRX) Stock Is Up 6.20%
As of Monday, July 20, InflaRx N.V.’s IFRX share price has surged by 6.20%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why InflaRx N.V.’s (IFRX) Stock Is Down 5.66%
As of Wednesday, July 08, InflaRx N.V.’s IFRX share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Jenna Brashear
Why InflaRx N.V.’s (IFRX) Stock Is Up 5.58%
As of Wednesday, July 01, InflaRx N.V.’s IFRX share price has surged by 5.58%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | IFRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $337.5 | $288.9 | 32% |
|
| Shares Out (Mil) | 134.4 | 54.0 | 68% |
|
| Institutional Ownership | 93.1% | 93.1% | 62% |
|
| Float (Mil) | 98.1 | 41.4 | 61% |
|
| Beta | 2.51 | 0.94 | 96% |
|
| Avg Daily Volume (000s) | 1,046 | 480 | 73% |
|
| Price Change (52-week) |
30.9% | 59.9% | 71% |
|
| Growth | IFRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (5.2%) | (10.1%) | 34% |
|
| EPS (5yr) | 12.3% | 15.9% | 51 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 35.1% | (15.6%) | 89% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.060) | ($0.308) | ($0.401) | |
| Month Ago EPS | ($0.061) | ($0.348) | ($0.434) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.061) | ($0.348) | ($0.434) | |
| Year/Year Chg | (41.7%) | (61.3%) | (44.0%) | |
| Financials | IFRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($45) | ($43) | 17% |
|
| EPS (TTM) | ($0.545) | ($1.500) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($27) | ($31) | 13% |
|
| Net Cash Flow (TTM) (Mil) | $153 | $2 | 81% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | $137 | $190 | 23% |
|
| Valuation | IFRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.03 | 2.84 | 50% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IFRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (32.3%) | (47.7%) | 16% |
|
| ROE | (38.2%) | (55.0%) | 18% |
|
| Liabilities to Assets | 12.4% | 29.6% | 8% |
|
| F-Score | 3 | 3 | 18% |
|
InflaRx N.V. did not pass any screens on 9/2/2026.
